Transport
Hot Springs National Park Hospital Holdings LLC
Hot Springs National Park Hospital Holdings LLC was paid $6.40M by Medicaid between Jan 2018 and Dec 2024, across 173 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 9.1% of everything it billed.
33Billing provider infoHOT SPRINGS NATIONAL PARK HOSPITAL HOLDINGS LLC
HOT SPRINGS, AR 71901
HOT SPRINGS, AR 71901
33aNPI1841241833assigned 05/13/2006
33bProvider typeLand Ambulance
28Total paid$6.40M
24GClaims447,675
24DCodes billed173
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Land Ambulance providers in Arkansas
Rank by total paid#4 of 50
Median peer was paid$678K
This provider vs. median9.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 59,571 | $697K | |
| 2019 | 74,666 | $1.20M | |
| 2020 | 61,632 | $893K | |
| 2021 | 56,787 | $748K | |
| 2022 | 71,904 | $997K | |
| 2023 | 72,885 | $1.14M | |
| 2024incomplete | 50,230 | $726K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.1% | 9,726 | 7,446 | $579K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.2% | 4,470 | 3,514 | $525K |
| 70450 | Computed tomography, head or brain; without contrast material | 7.1% | 5,111 | 4,156 | $452K |
| 80053 | Comprehensive metabolic panel | 6.0% | 34,825 | 23,865 | $381K |
| 59025 | Fetal non-stress test | 4.4% | 2,530 | 1,164 | $281K |
| 72125 | Computed tomography, cervical spine; without contrast material | 4.0% | 2,152 | 1,782 | $258K |
| 85027 | 3.6% | 46,718 | 30,843 | $232K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.7% | 8,803 | 6,242 | $172K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.6% | 3,555 | 2,488 | $168K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 1,985 | 1,598 | $135K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.1% | 4,174 | 3,091 | $134K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 3,701 | 2,795 | $131K |
161 more codes
| 36415 | Collection of venous blood by venipuncture | 1.9% | 29,766 | $124K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 3,231 | $118K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 15,648 | $107K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,825 | $103K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.3% | 360 | $85K |
| 87400 | 1.2% | 14,924 | $79K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 2,696 | $77K |
| 84703 | 1.2% | 9,190 | $77K | |
| 84484 | 1.2% | 12,354 | $76K | |
| 83880 | 1.1% | 3,924 | $72K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 2,205 | $72K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 11,412 | $71K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,434 | $63K |
| 86901 | <1% | 3,054 | $56K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 591 | $55K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,224 | $53K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,130 | $49K |
| 81000 | <1% | 15,707 | $48K | |
| 83735 | <1% | 10,162 | $47K | |
| 82077 | <1% | 3,666 | $46K | |
| 83690 | <1% | 7,709 | $45K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,749 | $45K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,772 | $42K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,231 | $41K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,114 | $38K |
| 87430 | <1% | 3,319 | $38K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 278 | $38K |
| 82962 | <1% | 8,313 | $37K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 182 | $36K |
| 82553 | <1% | 5,098 | $36K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 115 | $34K |
| 80061 | Lipid panel | <1% | 2,921 | $32K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,575 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 670 | $30K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,691 | $30K |
| 93458 | <1% | 752 | $29K | |
| 82550 | <1% | 6,403 | $28K | |
| 83605 | <1% | 3,463 | $26K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,455 | $26K |
| 86886 | <1% | 2,259 | $25K | |
| 80143 | <1% | 1,605 | $25K | |
| 80179 | <1% | 1,598 | $25K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,516 | $24K |
| 81002 | <1% | 9,507 | $23K | |
| 85730 | <1% | 7,101 | $23K | |
| 88304 | <1% | 1,216 | $23K | |
| 74018 | <1% | 1,422 | $23K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 243 | $22K |
| 80320 | <1% | 1,947 | $21K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,642 | $20K |
| 82150 | <1% | 3,362 | $20K | |
| 85610 | <1% | 8,748 | $20K | |
| 73560 | <1% | 1,223 | $19K | |
| 71250 | <1% | 298 | $18K | |
| 87040 | <1% | 2,073 | $17K | |
| 87071 | <1% | 3,387 | $16K | |
| 85379 | <1% | 2,409 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,637 | $16K |
| 72131 | <1% | 157 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,838 | $16K |
| 94729 | <1% | 997 | $15K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 114 | $15K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 528 | $14K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 656 | $14K |
| 86140 | <1% | 2,219 | $14K | |
| 87420 | <1% | 1,115 | $13K | |
| 84702 | <1% | 1,334 | $13K | |
| 73630 | <1% | 574 | $13K | |
| 73130 | <1% | 632 | $12K | |
| 82803 | <1% | 714 | $12K | |
| 87186 | <1% | 2,788 | $12K | |
| C1769 | Guide wire | <1% | 849 | $12K |
| 87088 | <1% | 1,693 | $11K | |
| 94060 | <1% | 1,093 | $11K | |
| 73610 | <1% | 702 | $11K | |
| 93017 | <1% | 823 | $10K | |
| 94726 | <1% | 946 | $10K | |
| 73030 | <1% | 710 | $10K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 213 | $10K |
| 97161 | <1% | 386 | $10K | |
| 87206 | <1% | 1,305 | $9K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 593 | $9K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 48 | $9K |
| 94664 | <1% | 2,548 | $8K | |
| 84439 | <1% | 656 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 403 | $7K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,752 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 376 | $6K |
| 84132 | <1% | 1,603 | $5K | |
| 82330 | <1% | 590 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 405 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 390 | $4K |
| 70486 | <1% | 28 | $4K | |
| 93971 | <1% | 136 | $4K | |
| 76801 | <1% | 123 | $4K | |
| 87077 | <1% | 527 | $3K | |
| 85007 | <1% | 1,179 | $3K | |
| 73110 | <1% | 160 | $3K | |
| 84100 | <1% | 1,601 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,212 | $2K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 30 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 83 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 28 | $2K |
| 96376 | <1% | 187 | $2K | |
| 82947 | <1% | 774 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 864 | $2K |
| 87210 | <1% | 310 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 588 | $2K |
| 72100 | <1% | 78 | $1K | |
| 85014 | <1% | 964 | $1K | |
| 90714 | <1% | 148 | $1K | |
| 80076 | <1% | 188 | $1K | |
| 84295 | <1% | 553 | $1K | |
| 74022 | <1% | 58 | $1K | |
| 73502 | <1% | 66 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 147 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 254 | $954.83 |
| 82728 | <1% | 82 | $933.54 | |
| 76641 | <1% | 26 | $876.91 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 28 | $872.40 |
| 84450 | <1% | 374 | $866.76 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 13 | $759.16 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 28 | $724.06 |
| 94618 | <1% | 243 | $692.97 | |
| 82140 | <1% | 165 | $658.51 | |
| 80164 | <1% | 73 | $645.44 | |
| 84460 | <1% | 355 | $619.86 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 165 | $572.77 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 168 | $562.83 |
| 85651 | <1% | 205 | $544.03 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $519.12 |
| 83525 | <1% | 41 | $511.12 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,199 | $455.87 |
| A9270 | Non-covered item or service | <1% | 3,962 | $242.88 |
| 82010 | <1% | 40 | $187.86 | |
| 85347 | <1% | 39 | $155.60 | |
| 84550 | <1% | 23 | $142.12 | |
| 83540 | <1% | 30 | $136.36 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 28 | $133.24 |
| 82607 | <1% | 15 | $115.86 | |
| 71020 | <1% | 175 | $110.41 | |
| 83550 | <1% | 14 | $104.63 | |
| 99152 | <1% | 492 | $65.36 | |
| 71010 | <1% | 419 | $51.96 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,207 | $51.20 |
| 82272 | <1% | 12 | $42.21 | |
| 82565 | <1% | 37 | $36.55 | |
| 76937 | <1% | 17 | $35.26 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 105 | $31.61 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 68 | $22.90 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 651 | $18.87 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 204 | $10.64 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 16 | $5.44 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 46 | $0.00 |
| 36600 | 0% | 103 | $0.00 | |
| 97116 | 0% | 150 | $0.00 | |
| 80303 | 0% | 278 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 16 | $0.00 |
| 97014 | 0% | 26 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 15 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.